ArticleInternational journal of clinical and experimental pathology2017
Reduced serum miR-138 is associated with poor prognosis of head and neck squamous cell carcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- miR-584-5p is a New Potential Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma.Current computer-aided drug design · 2025Article
- Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?Current oncology (Toronto, Ont.) · 2022Review
- MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies.Translational cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs (miRNAs) have been demonstrated to be potential biomarkers in various cancers including head and neck squamous cell carcinoma (HNSCC). The aim of this study was to assess the diagnostic and prognostic significance of serum miR-138 in HNSCC. Quantitative reverse-transcription PCR (qRT-PCR) was used to measure serum miR-138 levels in 113 HNSCC cases and 60 controls. The results showed that serum miR-138 expression was remarkably down-regulated in HNSCC patients compared to healthy volunteers. Moreover, serum miR-138 levels in 32 patients after receiving surgical treatment were significantly increased. Also, the receiver operating characteristic (ROC) curve analysis revealed that serum miR-138 could discriminate HNSCC patients from controls with high accuracy. Furthermore, a positive correlation was observed between decreased serum miR-138 and worse clinical outcome, as well as shorter survival. Then serum miR-138 was confirmed to be an independent prognostic indicator for HNSCC. Our results demonstrated that serum miR-138 might be a potential biomarker for detection and prognosis prediction of HNSCC.
Indexed as
Identifiers
31966362PMC6965797W3027639847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.